GE HealthCare Technologies Inc. saw a notable increase in its stock price, reflecting investor optimism.
GE HealthCare Technologies Inc. (NASDAQ:GEHC) went up yesterday by 3.04%, closing at CA$67.74. This rise came amid a backdrop of strategic moves and positive developments in the healthcare sector.
Advertisement
GE HealthCare Technologies Inc.
GEHC.US
GEHC.US
GE HealthCare Technologies Inc.
WealthAwesomeMarket cap
$30.81B
P/E
15.6x
Div. yield
0.21%
Div. / share
$0.14
52W high
$89.64
52W low
$58.72
1W change
+3.04%
Beta
0.85
Analyst Price Targets
Based on 21 analysts covering GEHC · as of Oct 12, 2026
Wall Street analysts forecast GEHC stock price to rise 22.4% over the next 12 months.
Consensus
Buy4.24 / 5.00
Avg. Target
C$82.90
+22.4% Upside
Current Price
C$67.74
Last close
Analyst Breakdown (21 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GEHC's historical volatility
30-Day Vol
23.1%
Annualized
90-Day Vol
34.9%
Annualized
Trend (90d)
+30.2%
Annualized drift
90d Mean
C$75.47
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$70.22 | C$64.84 – C$76.05 |
| 60 trading days | C$72.80 | C$65.03 – C$81.49 |
| 90 trading days | C$75.47 | C$65.73 – C$86.65 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are encouraged by GE HealthCare's recent strategic acquisition and its commitment to expanding its pharmaceutical diagnostics segment, which may drive future growth.
3.04% Increase in Stock Price
GE HealthCare's stock price increase reflects growing investor confidence in its strategic direction and market potential.
Bull case
The acquisition of Sofie Biosciences for $945 million is expected to boost GE HealthCare's capabilities in pharmaceutical diagnostics. This move could lead to higher revenue and a larger market share.
Bear case
Despite the positive movement, there are concerns about the company's organic growth and rising costs, which might affect profitability in the near term.
Strategic Acquisition Boosts Confidence
Advertisement
The recent announcement that GE HealthCare would acquire Sofie Biosciences for $945 million has generated excitement among investors. This acquisition is expected to strengthen GE HealthCare's position in the pharmaceutical diagnostics market, enhancing its product offerings and revenue potential.
Positive Market Sentiment
The stock's rise is also linked to a general positive sentiment in the healthcare sector, especially as companies like GE HealthCare shift towards AI-driven solutions and innovative diagnostics. This trend is viewed as a pathway to sustainable growth, despite some ongoing challenges.
Financial Performance and Future Outlook
While GE HealthCare's recent performance has shown some weaknesses, including concerns over organic growth, the latest developments suggest a potential turnaround. Investors are hopeful that the company's strategic initiatives will lead to improved financial results in the coming quarters.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
